BioLargo provides 2025 corporate outlook

The company said, “Having expanded the company’s strong foundation and achieved impressive revenue growth in 2024, BioLargo (BLGO) is now looking ahead to broaden the commercial traction of its operating segments and products even further in 2025. Each of BioLargo’s subsidiaries have potential to transform their respective markets and improve lives around the world. Based on the company’s track record of growth and adoption in new business segments underway, management believes 2025 could shape up to be another record year.BioLargo management has identified its key goals for the coming year: Uplist to a national stock exchange such as NASDAQ or the NYSE; Grow top line revenues and continue historical revenue growth performance; Complete the years-long effort to launch the Bioclynse wound irrigation solution for use during surgery through an industry-leading distribution partner; For PFAS, complete system installation in New Jersey, collect data from its operations, and sell more treatment systems; For the battery company, complete development of the commercial-sized Cellinity battery cell and packs, validate performance claims through third-party experts, and secure partners for its franchise business model to build factories around the world; Support the expanding growth of the Pooph pet odor control product line.”